Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer.
D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D005493:Folic Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*
D005493:Folic Acid Antagonists; D011743:Pyrimidines; C024530:piritrexim